Research analysts at Oppenheimer Holdings Inc. started coverage on shares of Regeneron Pharmaceuticals Inc (NDAQ:REGN) in a research note issued on Friday. The firm set a “market perform” rating on the stock.
Separately, Goldman Sachs Group Inc cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Thursday, February 16th.
Regeneron Pharmaceuticals (NDAQ:REGN) opened at 382.02 on Friday. The stock has a market capitalization of $40.29 billion and a price-to-earnings ratio of 49.62. Regeneron Pharmaceuticals has a 52-week low of $325.35 and a 52-week high of $452.96. The firm has a 50-day moving average price of $371.86 and a 200 day moving average price of $379.60.
Your IP Address:
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.